Yan Leyfman: New Insights into CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Yan Leyfman, Executive Committee Member at Music Beats Cancer, shared on LinkedIn:
“New insights into CAR T-cell therapy for R/R LBCL
Single-cell RNA sequencing of 57 CAR T products reveals striking biological differences between axi-cel (CD28) and tisa-cel (4-1BB) therapies.
Key findings:
Axi-cel is enriched in CD4/CD8 central memory & effector T cells with higher immune activation.
Tisa-cel shows more proliferative but less functional profiles.
Prolonged expansion during tisa-cel manufacturing reduces naïve/memory T cells. Differences may explain axi-cel’s greater efficacy and toxicity.
Suggests manufacturing process – not the CAR construct – limits tisa-cel potency.”
Title: Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing
Authors: Xiaoqing Yu, Michael D. Jain, Meghan A. Menges, Ling Cen, Jerald D. Noble, Reginald Atkins, Turab J. Mohammad, Christina A. Bachmeier, Samira Naderinezhad, Kayla Reid, Salvatore Corallo, Sean J. Yoder, Chaomei Zhang, Lanmin Zhang, Julieta Abraham Miranda, Bijal Shah, Julio C. Chavez, Rebecca S. Hesterberg, Luis Cuadrado Delgado, Constanza Savid-Frontera, Paulo C. Rodriguez, John L. Cleveland, Xuefeng Wang, Marco L. Davila, Frederick L. Locke
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023